论文部分内容阅读
目的探讨金黄色葡萄球菌感染经利奈唑胺治疗后临床效果及安全性问题。方法将90例金黄色葡萄球菌感染患者随机分为对照组45例(应用万古霉素治疗)、观察组45例(应用利奈唑胺治疗),对照两组患者用药一周后的临床症状、血培养结果,肝肾功变化、病原学改变及患者对药物的不良反应。结果对照组症状消失39例(86.6%)、血肌酐(245±10)μmol/L、血清总胆红素(30.71±1.1)μmol/L、细菌培养阳性5例(11%)、不良反应2例(4%);观察组症状消失45例(100%)、血肌酐(100±30)μmol/L、血清总胆红素(11.71±1.1)μmol/L、细菌培养阳性2例(4%)、不良反应1例(2%);观察组明显优于对照组(P<0.05)。结论利奈唑胺治疗金黄色葡萄球菌感染安全性可靠疗效确切。
Objective To investigate the clinical effects and safety of Staphylococcus aureus after linezolid treatment. Methods Ninety patients with Staphylococcus aureus infection were randomly divided into control group (n = 45) treated with vancomycin, observation group (n = 45) treated with linezolid and control group (n = Results, changes in liver and kidney function, etiological changes and patients with adverse drug reactions. Results The symptoms of the control group disappeared in 39 cases (86.6%), serum creatinine (245 ± 10) μmol / L, total serum bilirubin (30.71 ± 1.1) μmol / L, bacterial culture positive in 5 cases (4%). The symptom disappeared in 45 cases (100%), serum creatinine (100 ± 30) μmol / L and serum total bilirubin (11.71 ± 1.1) μmol / ), Adverse reactions in 1 case (2%); observation group was significantly better than the control group (P <0.05). Conclusion Linezolid is safe and reliable for the treatment of Staphylococcus aureus infection.